Read by QxMD icon Read

bioresorbable vascular scaffold

Giuseppe Tarantini, Giulia Masiero, Alberto Barioli, Valeria Paradies, Georgios Vlachojannis, Paola Tellaroli, Bernardo Cortese, Gaetano di Palma, Attilio Varricchio, Alfonso Ielasi, Bruno Loi, Giuseppe Steffenino, Daisuke Ueshima, Marco Mojoli, Pieter Smits
BACKGROUND: Patients with small vessel disease (SVD) are at higher risk of adverse events after PCI compared to non-SVD patients. In this subset, the use of bioresorbable vascular scaffolds (BVS) has raised particular concern. OBJECTIVE: We aimed to compare outcomes of Absorb BVS versus a 2nd-generation metallic everolimus-eluting stents (EES) in the SVD setting, by pooling patients from three large, prospective studies. METHODS: Patients with SVD (reference vessel diameter ≤2...
March 7, 2018: Catheterization and Cardiovascular Interventions
Antonio H Frangieh, Milosz Jaguszewski, Yoichi Imori, Slayman Obeid, Christian Templin
No abstract text is available yet for this article.
2018: Cardiology Journal
Christian-Hendrik Heeger, Anne-Sophie Schedifka, Felix Meincke, Tobias Spangenberg, Hendrick Wienemann, Felix Kreidel, Karl-Heinz Kuck, Alexander Ghanem, Martin W Bergmann
BACKGROUND: Suboptimal implantation of everolimus-eluting bioresorbable vascular scaffolds (EE-BVS) leading to strut malapposition and lack of neointima coverage has been hypothesized to be linked to late BVS-thrombosis. Optical coherence tomography (OCT) allows assessing subtle differences in BVS-healing. We aimed to link 6-months OCT-data on EE-BVS coverage and malapposition to implantation technique and clinical outcome. METHODS: Twenty-nine consecutive EE-BVS-patients were included...
March 7, 2018: Cardiology Journal
Pei-Jiang Wang, Nicola Ferralis, Claire Conway, Jeffrey C Grossman, Elazer R Edelman
Polymer-based bioresorbable scaffolds (BRS) seek to eliminate long-term complications of metal stents. However, current BRS designs bear substantially higher incidence of clinical failures, especially thrombosis, compared with metal stents. Research strategies inherited from metal stents fail to consider polymer microstructures and dynamics--issues critical to BRS. Using Raman spectroscopy, we demonstrate microstructural heterogeneities within polymeric scaffolds arising from integrated strain during fabrication and implantation...
February 26, 2018: Proceedings of the National Academy of Sciences of the United States of America
Michael Joner, Philipp Ruppelt, Philine Zumstein, Capucine Lapointe-Corriveau, Guy Leclerc, Anna Bulin, Maria Isabel Castellanos, Eric Wittchow, Michael Haude, Ron Waksman
AIMS: Because vascular restoration therapy using bioresorbable vascular scaffolds (BRS) remains an appealing concept to restore vasoreactivity, understanding of biodegradation remains paramount during preclinical testing. METHODS AND RESULTS: Qualitative characterization of biodegradation was performed in 41 DREAMS 1G up to 3 years, while degradation kinetics were acquired in 54 DREAMS 2G implanted into porcine coronary arteries for 28, 90 and 180 days, 1 and 2 years...
February 20, 2018: EuroIntervention
Christian Oliver Fallesen, Lisbeth Antonsen, Per Thayssen, Lisette Okkels Jensen, Pil Hyung Lee, Seung-Whan Lee, Seung-Jung Park, Elisabetta Moscarella, Giosafat Spitaleri, Salvatore Brugaletta
No abstract text is available yet for this article.
February 20, 2018: EuroIntervention
Anne Venkata Ganeshkumar, Rushikesh Sambhaji Patil, Irfan Khan Hamid
BACKGROUND AND OBJECTIVE: Studies conducted across the world have reported that the rates of major adverse cardiac events (MACE) following the use of bioresorbable vascular scaffolds (BVS) are comparable to that noted with traditional drug eluting stents (DES). However, there is limited data on the immediate and medium-term clinical outcomes following the use of the Absorb BVS (Abbott Vascular, Santa Clara, SA) in the Indian context. This study was conducted to determine real-world evidence on the immediate and medium-term clinical outcomes in all patients undergoing percutaneous coronary intervention (PCI) with the Absorb BVS...
January 2018: Indian Heart Journal
Charles Nicolais, Vladimir Lakhter, Hafeez Ul Hassan Virk, Partha Sardar, Chirag Bavishi, Brian O'Murchu, Saurav Chatterjee
PURPOSE OF REVIEW: In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades. RECENT FINDINGS: Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR...
February 12, 2018: Current Cardiology Reports
Elisabetta Moscarella, Alfonso Ielasi, Attilio Varricchio, Maria Carmen De Angelis, Bruno Loi, Giuseppe Tarantini, Paolo Calabrò, Bernardo Cortese, Pietro Mazzarotto, Gabriele Gabrielli, Francesco Pisano, Michela Facchin, Leonardo Misuraca, Valerio Lucci, Roberto Gistri, Gabriele Tumminello, Luciano Moretti, Alessandro Colombo, Alessandro Durante, Massimo Fineschi, Davide Piraino, Maurizio Ferrario, Sebastian Coscarelli, Annamaria Nicolino, Maurizio Tespili, Donatella Corrado, Giuseppe Steffenino
BACKGROUND: The bioresorbable vascular scaffold (BVS) technology may be an appealing option in ST-segment elevation myocardial infarction (STEMI) patients. However, the available evidence on its use in this challenging subset is limited. METHODS: Registro Absorb Italiano (RAI) is a multicenter, prospective registry that aims to assess BVS performance through a 5-year follow-up of all consecutive patients who undergone at least 1 successful BVS implantation. As a part of it, a subgroup analysis in STEMI patients was performed and the outcomes of this cohort compared to the remaining population (defined as "non-STEMI") are reported here...
February 3, 2018: International Journal of Cardiology
Vikas Thondapu, Erhan Tenekecioglu, Eric K W Poon, Carlos Collet, Ryo Torii, Christos V Bourantas, Cheng Chin, Yohei Sotomi, Hans Jonker, Jouke Dijkstra, Eve Revalor, Frank Gijsen, Yoshinobu Onuma, Andrew Ooi, Peter Barlis, Patrick W Serruys
Aims: As a sine qua non for arterial wall physiology, local hemodynamic forces such as endothelial shear stress (ESS) may influence long-term vessel changes as bioabsorbable scaffolds dissolve. The aim of this study was to perform serial computational fluid dynamic (CFD) simulations to examine immediate and long-term haemodynamic and vascular changes following bioresorbable scaffold placement. Methods and results: Coronary arterial models with long-term serial assessment (baseline and 5 years) were reconstructed through fusion of intravascular optical coherence tomography and angiography...
February 2, 2018: European Heart Journal
Frédéric Maes, Olivier Costerousse, Tomas Cieza, Mélaine Henry, Jean-Pierre Déry, Gérald Barbeau, Robert Delarochellière, Jean-Michel Paradis, Eric Larose, Can M Nguyen, Charles Pirlet, Rosaire Mongrain, Olivier F Bertrand
BACKGROUND: Whether polymeric bioresorbable vascular scaffolds (BVS) implantation with transradial approach is feasible and safe is unknown. We compared the feasibility and safety of the transradial approach for BVS delivery with metallic drug-eluting stents (DES). METHODS: We identified 118 consecutive patients who underwent BVS implantation and we compared 30-days and 1-year results with 118 matched patients with DES. Patients were matched for age, sex, risk factors and clinical indication...
January 6, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Jessica Roa-Garrido, Antonio E Gomez-Menchero, Ahmed Mahmoud El Amrawy, Rosa Cardenal-Piris, Santiago Camacho-Freire, Jose Francisco Diaz-Fernandez
No abstract text is available yet for this article.
December 27, 2017: Canadian Journal of Cardiology
Xiao-Zeng Wang, Yao-Jun Zhang, Guo-Sheng Fu, Quan-Min Jing, Bo Xu, Ya-Ling Han
BACKGROUND: Tremendous efforts have been made to establish the concept of vascular restoration therapy with a fully bioresorbable scaffold for coronary artery disease. With an improved scaffold design and technologies, the novel NeoVas scaffold has shown promising clinical performance at 6 months follow-up. OBJECTIVE: The aim of this study was to investigate the 1 year clinical outcomes and multislice computed tomography (MSCT) angiographic results after implantation of the NeoVas scaffold in patients with single de novo coronary artery lesions...
February 2, 2018: Catheterization and Cardiovascular Interventions
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
Coronary lesions at bifurcation sites are frequent and still remain a challenging subset for the interventional cardiologist. Although in the last years the provisional stenting technique has shown more consistent results, coronary bifurcation interventions still share a worse procedural success rate and increased rates of mid- and long-term cardiac events. Most of the dedicated devices proposed in the last few years have failed to show improved results when compared with standard devices. The broader use of imaging techniques, such as intravascular ultrasound and optical coherence tomography, lead to a better understanding of the real anatomy of bifurcations and has shown to be a great tool for percutaneous coronary intervention optimization...
January 26, 2018: Future Cardiology
Constantin von Zur Mühlen, Simon Reiss, Axel J Krafft, Lisa Besch, Marius Menza, Manfred Zehender, Timo Heidt, Alexander Maier, Thomas Pfannebecker, Andreas Zirlik, Jochen Reinöhl, Peter Stachon, Ingo Hilgendorf, Dennis Wolf, Philipp Diehl, Tobias Wengenmayer, Ingo Ahrens, Christoph Bode, Michael Bock
BACKGROUND: Evaluation of recurrent angina after percutaneous coronary interventions is challenging. Since bioresorbable vascular scaffolds (BVS) cause no artefacts in magnetic resonance imaging (MRI) due to their polylactate-based backbone, evaluation of vascular patency by MRI might allow for non-invasive assessment and triage of patients with suspected BVS failure. METHODS: Patients with polylactate-based ABSORB-BVS in proximal coronary segments were examined with 3 Tesla MRI directly (baseline) and one year after implantation...
2018: PloS One
Elisabetta Moscarella, Akihito Tanaka, Alfonso Ielasi, Bernardo Cortese, Sebastian Coscarelli, Maria Carmen De Angelis, Davide Piraino, Azeem Latib, Giulietta Grigis, Renatomaria Bianchi, Dario Buccheri, Paolo Calabrò, Maurizio Tespili, Pedro Silva Orrego, Antonio Colombo, Attilio Varricchio
OBJECTIVES: to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. BACKGROUND: BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. METHODS: We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014...
January 22, 2018: Catheterization and Cardiovascular Interventions
Laura S Kerkmeijer, Erhan Tenekecioglu, Joanna J Wykrzykowska
The percutaneous coronary intervention has undergone rapid evolution over the last 40 years and has become one of the most widely performed medical procedures. The introduction of intracoronary stents improved the safety and efficacy of percutaneous coronary intervention. But with the advent of stenting, a new potentially fatal enemy emerged: stent thrombosis. Ever since, adjunct pharmacological therapy, stent technique and technology have been adjusted to reduce the risk of stent thrombosis. The aim of the present article is to provide an overview of past, present and future aspects of percutaneous intervention in relation to stent thrombosis...
January 15, 2018: Polish Archives of Internal Medicine
Davide Capodanno, Sergio Buccheri, Sara Romano, Piera Capranzano, Bruno Francaviglia, Corrado Tamburino
BACKGROUND: Relative benefits of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) are expected to accrue after complete bioresorption. METHODS AND RESULTS: We built a decision analytic Markov model comparing BVS and EES for a contemporary percutaneous coronary intervention population. Procedure-related morbidity and outcome data from the available literature were used to derive model probabilities. The net benefit of BVS and EES was estimated in terms of quality-adjusted life expectancy...
January 2018: Circulation. Cardiovascular Interventions
Davide Capodanno
Bioresorbable scaffolds (BRS) represent a novel paradigm in the 40-year history of interventional cardiology. Restoration of cyclic pulsatility and physiologic vasomotion, adaptive vascular remodeling, plaque regression, and removal of the trigger for late adverse events are expected BRS benefits over current metallic drug-eluting stents. However, first-generation BRS devices have significant manufacturing limitations and rely on optimal implantation technique to avoid experiencing an excess of clinical events...
January 2018: Korean Circulation Journal
Jeehoon Kang, Hyo-Soo Kim
No abstract text is available yet for this article.
January 11, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"